2Barbara W,Heike P,Urban JS,et al.Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib[J].Blood,2004,103(4):1495-1498.
3O' Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic - phase chronic myeloid leukemia [ J ]. N Engl J Med,2003,348 (13) :994 - 1004.
4Buchdunger E, Matter A, Dmker BJ. Bcr - Abl inhibition as a modality of CML thempeutics [ J ]. Biochim Biophys Acta, 2001,1551(1) :M11 - M18.
5Shaffer LG,Tommerup N. SCN:An International System for Human Cytogenetic Nomenclature [ S ]. Karger S Basel, 2005.
6Gallipoli P, Abraham SA, Holyoake TL. Hurdles toward a cure for CML: the CML stem cell [ J ]. Hematol Oncol Clin North Am,2011, 259(5) :51 -66.
7Hochhaus A, Druker B, Sawyers C, et al. Favorable long - term follow up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic - phase chronic myeloid leukemia after failure of interferon - alpha treatment[ J ]. Blood,2008,111 (3) : 1039 - 1043.
8Druker BJ,O' Brien SG, Guilhot F, et al. Five - year follow- up of patients receiving imatinib for chronic myeloid leukemia[J]. N Engl J Med,2006,355(7) :2408 -2417.
9Martin Henkes, Heiko van der Kuip, Walter E Aulitzky. Therapeutic options for chronic myeloid leukemia: focus on imatinib ( Glivec, Gleevec^TM ) [J]. Ther Clin Risk Manag, 2008, 4(1): 163-187.
10Quint s - Cardama A, Kantarjian HM, Coaes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia [ J ]. Cancer Control, 2009, 16 (2) :122 -131.
